Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials.
暂无分享，去创建一个
E. Rahimy | D. Boyer | R. Vitti | Namrata Saroj | R. Khurana | Alyson J. Berliner | Andrea Gibson | K. Chu | W. Joseph | Yenchieh Cheng | David S. Boyer | Karen W. Chu | Rahul N. Khurana | W. Anthony Joseph